Adrenocortical carcinoma (ACC) is a rare disease caused by cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. The adrenal glands lie on top of the kidneys. They play a major role in the endocrine system, which is the system that produces and regulates hormones. The causes of primary adrenocortical carcinoma are unknown. However adrenocortical carcinoma can also be secondary cancer. A secondary cancer is what happens when another form of cancer spreads to the adrenal glands. Adrenocortical carcinoma can occur at any age, but there is a bimodal distribution with a first peak at childhood between 1–6 years old and the second peak in the fourth to the fifth decade of life. During the past decade, collaborative efforts have been made to improve the ACC treatment. 

Scope of the Report:

This report studies the Adrenocortical Carcinoma Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Adrenocortical Carcinoma Treatment market by product type and applications/end industries.

Some of the key factors that are driving the adrenocortical carcinoma treatment market are increasing the prevalence of cancer, rising government involvement, increasing funding from various government and non-government organizations. Also, ethical acceptance of adrenocortical carcinoma treatment and high unmet needs in some regions are driving the adrenocortical carcinoma treatment market. However, less awareness and high cost involved in treatment are restraining the global adrenocortical carcinoma treatment market. Also, the introduction of generic drugs in some countries is restraining the growth of adrenocortical carcinoma treatment market. Also, despite the high cost involved in R&D, pharmaceutical companies are showing increased interest in this field. This is expected to offer good potential for adrenocortical carcinoma treatment market.

The global Adrenocortical Carcinoma Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Adrenocortical Carcinoma Treatment.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

ArQule

EnGeneIC

Exelixis

Merck

Millendo Therapeutics

Orphagen Pharmaceuticals

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Localized Adrenocortical Carcinoma

Metastatic Adrenocortical Carcinoma

Market Segment by Applications, can be divided into

Hospitals

Ambulatory Surgical Centers

Clinics

Cancer Research Institutes

Table of Contents

1 Adrenocortical Carcinoma Treatment Market Overview

1.1 Product Overview and Scope of Adrenocortical Carcinoma Treatment

1.2 Classification of Adrenocortical Carcinoma Treatment by Types

1.2.1 Global Adrenocortical Carcinoma Treatment Revenue Comparison by Types (2017-2023)

1.2.2 Global Adrenocortical Carcinoma Treatment Revenue Market Share by Types in 2017

1.2.3 Localized Adrenocortical Carcinoma

1.2.4 Metastatic Adrenocortical Carcinoma

1.3 Global Adrenocortical Carcinoma Treatment Market by Application

1.3.1 Global Adrenocortical Carcinoma Treatment Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Hospitals

1.3.3 Ambulatory Surgical Centers

1.3.4 Clinics

1.3.5 Cancer Research Institutes

1.4 Global Adrenocortical Carcinoma Treatment Market by Regions

1.4.1 Global Adrenocortical Carcinoma Treatment Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Adrenocortical Carcinoma Treatment Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Adrenocortical Carcinoma Treatment Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Adrenocortical Carcinoma Treatment Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Adrenocortical Carcinoma Treatment Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Adrenocortical Carcinoma Treatment Status and Prospect (2013-2023)

1.5 Global Market Size of Adrenocortical Carcinoma Treatment (2013-2023)

2 Manufacturers Profiles

2.1 ArQule

2.1.1 Business Overview

2.1.2 Adrenocortical Carcinoma Treatment Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 ArQule Adrenocortical Carcinoma Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.2 EnGeneIC

2.2.1 Business Overview

2.2.2 Adrenocortical Carcinoma Treatment Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 EnGeneIC Adrenocortical Carcinoma Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.3 Exelixis

2.3.1 Business Overview

2.3.2 Adrenocortical Carcinoma Treatment Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Exelixis Adrenocortical Carcinoma Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.4 Merck

2.4.1 Business Overview

2.4.2 Adrenocortical Carcinoma Treatment Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Merck Adrenocortical Carcinoma Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.5 Millendo Therapeutics

2.5.1 Business Overview

2.5.2 Adrenocortical Carcinoma Treatment Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Millendo Therapeutics Adrenocortical Carcinoma Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.6 Orphagen Pharmaceuticals

2.6.1 Business Overview

2.6.2 Adrenocortical Carcinoma Treatment Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Orphagen Pharmaceuticals Adrenocortical Carcinoma Treatment Revenue, Gross Margin and Market Share (2016-2017)

3 Global Adrenocortical Carcinoma Treatment Market Competition, by Players

3.1 Global Adrenocortical Carcinoma Treatment Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Adrenocortical Carcinoma Treatment Players Market Share

3.2.2 Top 10 Adrenocortical Carcinoma Treatment Players Market Share

3.3 Market Competition Trend

4 Global Adrenocortical Carcinoma Treatment Market Size by Regions

4.1 Global Adrenocortical Carcinoma Treatment Revenue and Market Share by Regions

4.2 North America Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

4.3 Europe Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

4.5 South America Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

5 North America Adrenocortical Carcinoma Treatment Revenue by Countries

5.1 North America Adrenocortical Carcinoma Treatment Revenue by Countries (2013-2018)

5.2 USA Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

5.3 Canada Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

5.4 Mexico Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

6 Europe Adrenocortical Carcinoma Treatment Revenue by Countries

6.1 Europe Adrenocortical Carcinoma Treatment Revenue by Countries (2013-2018)

6.2 Germany Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

6.3 UK Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

6.4 France Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

6.5 Russia Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

6.6 Italy Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Adrenocortical Carcinoma Treatment Revenue by Countries

7.1 Asia-Pacific Adrenocortical Carcinoma Treatment Revenue by Countries (2013-2018)

7.2 China Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

7.3 Japan Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

7.4 Korea Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

7.5 India Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

8 South America Adrenocortical Carcinoma Treatment Revenue by Countries

8.1 South America Adrenocortical Carcinoma Treatment Revenue by Countries (2013-2018)

8.2 Brazil Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

8.3 Argentina Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

8.4 Colombia Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Adrenocortical Carcinoma Treatment by Countries

9.1 Middle East and Africa Adrenocortical Carcinoma Treatment Revenue by Countries (2013-2018)

9.2 Saudi Arabia Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

9.3 UAE Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

9.4 Egypt Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

9.5 Nigeria Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

9.6 South Africa Adrenocortical Carcinoma Treatment Revenue and Growth Rate (2013-2018)

10 Global Adrenocortical Carcinoma Treatment Market Segment by Type

10.1 Global Adrenocortical Carcinoma Treatment Revenue and Market Share by Type (2013-2018)

10.2 Global Adrenocortical Carcinoma Treatment Market Forecast by Type (2018-2023)

10.3 Localized Adrenocortical Carcinoma Revenue Growth Rate (2013-2023)

10.4 Metastatic Adrenocortical Carcinoma Revenue Growth Rate (2013-2023)

11 Global Adrenocortical Carcinoma Treatment Market Segment by Application

11.1 Global Adrenocortical Carcinoma Treatment Revenue Market Share by Application (2013-2018)

11.2 Adrenocortical Carcinoma Treatment Market Forecast by Application (2018-2023)

11.3 Hospitals Revenue Growth (2013-2018)

11.4 Ambulatory Surgical Centers Revenue Growth (2013-2018)

11.5 Clinics Revenue Growth (2013-2018)

11.6 Cancer Research Institutes Revenue Growth (2013-2018)

12 Global Adrenocortical Carcinoma Treatment Market Size Forecast (2018-2023)

12.1 Global Adrenocortical Carcinoma Treatment Market Size Forecast (2018-2023)

12.2 Global Adrenocortical Carcinoma Treatment Market Forecast by Regions (2018-2023)

12.3 North America Adrenocortical Carcinoma Treatment Revenue Market Forecast (2018-2023)

12.4 Europe Adrenocortical Carcinoma Treatment Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Adrenocortical Carcinoma Treatment Revenue Market Forecast (2018-2023)

12.6 South America Adrenocortical Carcinoma Treatment Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Adrenocortical Carcinoma Treatment Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Adrenocortical Carcinoma Treatment Picture

Table Product Specifications of Adrenocortical Carcinoma Treatment

Table Global Adrenocortical Carcinoma Treatment and Rev